

### LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17595 (BOT)	SERIAL NO.: 10/621,054
APPLICANT CAERS, J. et al.	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE: July 15, 2003	GROUP 3761

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CA	AA	2005-0148935	07JUL2005	DIMITROVA et al.	604	116	29DEC2003
CA	AB	4,580,561	08APR1986	WILLIAMSON	128	303B	
CA	AC	4,736,526	12APR1988	HSIA	33	565	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						

### OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	CA	Bigalke, Hans et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> ; <u>Brain Res</u> ; 1985; 360: pp 381-24
	CB	Bigalke, H. et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord</i> ; <u>Naunyn Schmiedeberg's Arch Pharmacol</u> ; 1981; 316; pp 244-51
	CC	Binz, Thomas et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> ; <u>J Biochem</u> ; (Tokyo) 1990 Jun 5; 265(16); pp 9153-8
	CD	Boyd, R.S. et al., <i>The insulin secreting B-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A</i> ; <u>Mov. Disorders</u> ; 1995; May; 10(3); 376
	CE	Bushara, K.; <i>Botulinum toxin and rhinorrhea</i> ; <u>Otolaryngol Head Neck Surg</u> , 1996; 114(3); 507
	CF	Ferrari, David M. et al., <i>The protein disulphide-isomerase family: unravelling a string of folds</i> ; <u>Biochem J</u> ; 1999 (339) pp 1-10
	CG	Grimalt, R. et al.; <i>Multi-injection plate for Botulinum toxin application in the treatment of axillary hyperhidrosis</i> ; <u>Dermatol Surg</u> ; 2001, Jun; 27(6); 543-544
	CH	Habermann, E.; <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> ; <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> ; 1974; 281; 47-56
	CI	Habermann, E., <i>Inhibition by tetanus and botulinum A toxin of the release of {3H}noradrenaline and {3H}GABA from rat brain homogenate</i> ; <u>Experientia</u> ; 1988, Mar 15; 44(3) pp 224-6
↓	CJ	Habermann, E. et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain</i> ; <u>J Neurochem</u> ; Vol 51, No 2 1988; pp 522-7

EXAMINER /Catharine Anderson/

DATE CONSIDERED 03/03/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17595 (BOT)		SERIAL NO.: 10/621,054
APPLICANT	CAERS, J. et al.	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE:	July 15, 2003	GROUP 3761

CA	CK	Jankovic, Joseph et al., <u>Therapy with Botulinum Toxin</u> ; Marcel Dekker, Inc.; pp 5
	CL	Marjama-Lyons, Jill et al., <u>Tremor-Predominant Parkinson's Disease</u> ; <u>Drugs &amp; Aging</u> ; 2000; April 16 (4) pp273-278
	CM	Moyer, E. et al.; <u>Botulinum Toxin Type B: Experimental and Clinical Experience</u> , pp 71-85 (chapter 6) of <u>Therapy With Botulinum Toxin</u> , edited by Jankovic, J. et al.; Marcel Dekker, Inc. 1994
	CN	Naumann, Markus et al., <u>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</u> ; <u>European Journal of Neurology</u> ; 1999, Vol 6 (suppl 4) pp S111-5
	CO	Naumann, M.; <u>Botulinum toxin type A in the treatment of focal hyperhidrosis</u> ; <u>J. Cutaneous Laser Therapy</u> , 2001;3(1); 42-43
	CP	Pearce, Bruce et al., <u>Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine</u> ; <u>Toxicon</u> ; 1997; 35 (9); pp 1373-412 at 1393
	CQ	Sanchez-Prieto, Jose et al., <u>Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes</u> ; <u>Eur J Biochem</u> ; 1987 Jun; 165 (3); pp 675-81
	CR	Schantz, Edward J. et al., <u>Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine</u> ; <u>Microbiol Review</u> ; 1992 Mar; 56 (1); pp 80-99
	CS	Singh; <u>Critical Aspects of Bacterial Protein Toxins</u> ; pp63-84 (chapter 4) of <u>Natural Toxins II</u> , edited by B.R. Singh et al., Plenum Press, New York 1996
	CT	Sloop, Richard R. et al., <u>Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</u> ; <u>Neurology</u> ; 1997, Jan; 48 (1); pp 249-53
↓	CU	Weigand et al.; <u>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</u> ; <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> ; 1976, 292; 161-165

EXAMINER /Catharine Anderson/

DATE CONSIDERED 03/03/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.